Revolution Medicines, a Phase 1/2 biotech developing targeted cancer therapies using the RAS pathway, announced terms for its IPO on Monday.



The Redwood City, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Revolution Medicines would command a fully diluted market value of $850 million.



Revolution Medicines was founded in 2015 and booked $48 million in collaboration revenue for the 12 months ended September 30, 2019. It plans to list on the Nasdaq under the symbol RVMD. J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities are the joint bookrunners on the deal. It is expected to price during the week of February 10, 2020.



The article Oncology biotech Revolution Medicines sets terms for $150 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.



Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.